Answers are grounded in this paper and cite their sources.
Autologous hematopoietic stem cell transplantation has emerged as a highly effective treatment strategy for selected patients with active relapsing multiple sclerosis and is now being investigated in other neuroinflammatory diseases, including neuromyelitis optica spectrum disorder and stiff person syndrome, among others. Accumulating evidence from observational studies and clinical trials demonstrated sustained suppression of inflammatory disease activity in multiple sclerosis, whereas evidence in other neuroinflammatory diseases remains largely limited to case series. Major professional bodies have endorsed autologous hematopoietic stem cell transplantation as an option for active multiple sclerosis refractory to high-efficacy disease-modifying therapies. Nevertheless, even within the multiple sclerosis field, critical questions remain unresolved. The optimal conditioning regimen and benefit of CD34+ cell selection have not been established. Patient selection criteria require further refinement. Where to place autologous hematopoietic stem cell transplantation among current treatment options remains uncertain. Ongoing randomized trials are expected to substantially advance the evidence base.
No takes yet. Share an insight, caveat, or question.
Afzal et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: